In light of the observed increase in spleen weight following bortezomib treatment, our findings suggest ASCs represent a minor population in the spleen, whose non-specific reduction does not influence hypertension compared with interventions such as B cell depletion (6), splenectomy (52) or IgE blockade (35). Here, IGHE is linked to hypertensive disorder.